NeuroBo Pharmaceuticals, a clinical-stage biotechnology company, has completed its merger with United States-based Gemphire Therapeutics on 31 December2019, it was reported yesterday.

The new integrated company is called NeuroBo Pharmaceuticals and it started trading on the Nasdaq exchange under the ticker 'NRBO' on 31 December 2019. The company is to concentrate on advancing its clinical-stage pipeline for neurodegenerative diseases.

The integrated company is to operate under the leadership of NeuroBo's new president and chief executive officer, Richard J Kang, PhD, and chief medical officer, Mark Versavel, MD, PhD, MBA. The integrated organisation's board of directors includes seven members, two from the former NeuroBo board, one director from the former Gemphire board and four newly appointed members designated by NeuroBo prior to the merger. Ms Na Yeon (Irene) Kim, MS, MBA, has been appointed as chairman of the board. The integrated company's corporate headquarters is located in Boston, Massachusetts.